Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.32 |
| ▸ | TPMT | P51580 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31210105 | 1.00 | TUBB1 (0.32) | TUBB1TPMTALDH1A1HSD17B10MCL1 | |
| SCHEMBL448336 | 0.83 | ALDH1A1 (0.39) | TUBB1ALDH1A1HSD17B10TDP1ACHE | |
| SCHEMBL28940453 | 0.82 | GRIN2D (0.33) | TUBB1TPMTHSD17B10MCL1TDP1 | |
| SCHEMBL12326410 | 0.80 | ACHE (0.33) | TPMTHSD17B10MCL1ACHE | |
| SCHEMBL24899658 | 0.78 | TPMT (0.34) | TUBB1TPMTMCL1ACHE | |
| SCHEMBL7976367 | 0.74 | TUBB1 (0.41) | TUBB1ALDH1A1ACHE | |
| SCHEMBL1099372 | 0.74 | ACHE (0.36) | TUBB1ALDH1A1HSD17B10TDP1ACHE | |
| SCHEMBL2036050 | 0.73 | TDP1 (0.44) | TUBB1TPMTALDH1A1TDP1 | |
| SCHEMBL9149201 | 0.73 | HSD17B10 (0.38) | TUBB1ALDH1A1HSD17B10TDP1ACHE | |
| SCHEMBL9377977 | 0.73 | CA2 (0.41) | TUBB1TPMTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635494-A2 | AMIDO HETEROAROMATIC COMPOUNDS | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4514782-B1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-12291524-B2 | Amido heteroaromatic compounds | ASTRAZENECA AB (SE) | 2025-05-06 | — | — | US | disclosed |
| EP-4514782-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | Astrazeneca AB (SE) | 2025-03-05 | — | — | EP | disclosed |
| US-20250011311-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2025-01-09 | — | — | US | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2023222850-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023222850-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| EP-3050882-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2545045-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8580962-B2 | Spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD. (IT) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291524-B2 | Amido heteroaromatic compounds | CYP7A1, SLC10A1, CYP11B2 | TUBB1 2198/4885TPMT 248/4885ALDH1A1 299/4885 |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | TUBB1 2198/4885TPMT 248/4885ALDH1A1 299/4885 |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GPR65, GRIK5 | TUBB1 3760/4885TPMT 2994/4885ALDH1A1 1514/4885 |
| US-20250011311-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | TUBB1 2198/4885TPMT 248/4885ALDH1A1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.